James Marion

James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Amtech Systems Inc. (Nasdaq: ASYS) Reports Revenues – Shares Rocket

Amtech Systems, Inc. – Nasdaq: ASYS

Shares of Tempe, AZ-based Amtech Systems Inc have been up over 50% in today’s trading on extremely heavy volume. Amtech announced fiscal year 2017 year-to-date order bookings through January 20, 2017 are approximately $84 million. This includes solar orders of $60 million. That figure represents around one-third of their total sales for 2016 ($120.3 million).

ASYS, traded on the Nasdaq, ended yesterday at $4.11 but the news quickly sent shares to $6.17. The average trading volume for ASYS is just over 30,000 shares per day but as of 2:24 PM EST share volume was over 1,000,000 shares.

Amtech Systems, Inc. manufactures and sells capital equipment and related consumables to manufacture solar cells, LED, and semiconductor devices. Although they operate primarily in the United States, they also have operations and sales units in Asia, Europe, and internationally.

One firm follows Amtech Systems Inc. Their analysts have rated shares of ASYS as a “Strong Buy” with a price target of $8.75.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/24/2017
Ticker Symbol ASYS
Last Price a/o 1:13 PM EST  $                      5.75
Average Volume 30,100
Market Cap $52.48 million
Sales $120.3 milion
Shares Outstanding 12.77 million
Share Float 10.19 million
Shortable Yes
Optionable Yes
Inside Ownership 22.82%
Short Float 0.95%
Short Interest Ratio 3.22
Quarterly Return -7.22%
YTD Return -3.29%
Year Return -20.81%

Marinus Pharmaceuticals (Nasdaq: MRNS) Up on Massive Volume

Marinus Pharmaceuticals, Inc. – Nasdaq: MRNS

Massive volumes are being traded in nano-cap Marinus Pharmaceuticals. Traded on the Nasdaq under ticker MRNS, volumes are over nine times their daily average. The increased volumes appear to be in response to news of positive preliminary data from the initial CDKL5 patients enrolled in its ongoing Phase 2 open-label study evaluating its CNS-selective GABAA modulator, ganaxolone, as a treatment for orphan, genetic disorders. Marinus is currently evaluating ganaxolone in orphan pediatric indications for the treatment of genetic seizure and behavior disorders, and preparing to initiate Phase 2 studies in status epilepticus, an orphan indication, and postpartum depression.

CDKL5 is a serious and rare genetic disorder that is caused by a mutation of the cyclin-dependent kinase-like 5 (CDKL5) gene, located on the X chromosome. It predominantly affects girls and is characterized by early-onset, difficult-to-control seizures and severe neuro‑developmental impairment.

Two firms follow Marinus Pharmaceuticals. One rates MRNS as a “Strong Buy” and the other rates the shares as a “Hold”. The consensus price target for MRNS is $2.50. Shareholders of MRNS have never experienced a positive EPS and last year MRNS had an EPS loss of $1.67 on zero reported sales.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

Immune Pharmaceuticals (Nasdaq: IMNP) Makes Major Announcement

Immune Pharmaceuticals, Inc. – Nasdaq: IMNP

Immune Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing therapeutics for the treatment of immuno-inflammatory diseases and cancers, announced today that it has entered an exclusive sub-license agreement with SATT Sud-Est, a French Technology Transfer Office, to develop, use, manufacture and commercialize mono- and bispecific antibodies targeting components of the tumor microenvironment and angiogenic factors. The research program will be carried out under the responsibility of Inserm, CNRS (National Center for Scientific Research), UCA (University Cote d’Azur), CSM (Scientific Center of Monaco), and Immune Pharmaceuticals. 

The nano-cap firm trades on the Nasdaq under ticker IMNP. IMNP shares are fractionally down in early trading. EPS for IMNP has never been positive. The largest loss was in 2011 ($9.17). In 2015 IMNP shares experienced a loss of $0.90. The only year sales were reported by Immune Pharmaceuticals, Inc was 2011 when they posted $900k in sales.

Two firms follow Immune Pharmaceuticals and each rates IMNP as a “Strong Buy” with a consensus price target of $2.50.  

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/23/2017
Ticker Symbol IMNP
Last Price a/o 9:46 AM EST  $                      0.21
Average Volume 6.22 million
Market Cap $26.9 million
Sales $-
Shares Outstanding 123.4 million
Share Float 123.4 million
Shortable Yes
Optionable No
Inside Ownership 5.90%
Short Float 6.49%
Short Interest Ratio 1.29
Quarterly Return -9.17%
YTD Return 19.78%
Year Return -58.87%

Catabasis Pharmaceuticals Inc. (Nasdaq: CATB) Product Results Published

Catabasis Pharmaceuticals Inc. – Nasdaq: CATB

Thinly traded nano-cap Catabasis Pharmaceuticals is up over 15% in the pre-market on small volumes. The Journal of Clinical Pharmacology published results from a Phase 1 study assessing Catabasis Pharmaceutical’s edasalonexent product in adult subjects. Edasalonexent is being developed to treat Duchenne muscular dystrophy (DMD). The results showed that edasalonexent was safe, well-tolerated and inhibited activated NF-kB.

Catabasis Pharmaceuticals Inc. trades on the Nasdaq under ticker CATB. Catabasis Pharmaceuticals uses their proprietary SMART linker drug discovery platform to conjugate two separate bioactives with known pharmacological activity. The technology renders the bioactive inactive in the circulation so safety of the molecule may be improved compared to the individual separate bioactives. Their newly-created molecules act like a two-pronged drug candidate with potential for enhanced efficacy and improved safety and tolerability compared to individual separate bioactives.

Four firms follow Catabasis Pharmaceuticals Inc. All four rate CATB shares as a “Strong Buy” with a price target of $16. However, CATB shareholders have never experienced a positive EPS. In 2015 CATB EPS was the worst since 2012 with a loss of $2.13. CATB has no reported sales.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/19/2017
Ticker Symbol CATB
Last Price a/o 9:22 AM EST  $                      4.60
Average Volume 116,000
Market Cap $76.53 million
Sales $-
Shares Outstanding 18.44 million
Share Float 17.2 million
Shortable Yes
Optionable No
Inside Ownership 4.20%
Short Float 1.42%
Short Interest Ratio 2.1
Quarterly Return -12.82%
YTD Return 14.96%
Year Return -23.71%

NVE Corporation (Nasdaq: NVEC) Posts Earnings

NVE Corporation – Nasdaq: NVEC

Eden Prarie, MN-based NVE Corporation announced financial results. The nanotechnology firm, traded on the Nasdaq under ticker NVEC, increased total revenue from $6.02 million in Q3 of the prior year quarter to $7.46 million. Net income for the third quarter of fiscal 2017 increased 35% to $3.48 million, or $0.72 per diluted share, compared to $2.58 million, or $0.53 per share, for the prior-year quarter. 

For the first nine months of fiscal 2017, total revenue decreased 1% to $21.5 million from $21.6 million for the first nine months of the prior year. The decrease was due to a 30% decrease in contract research and development revenue, partially offset by a 3% increase in product sales. Net income increased 2% to $9.92 million, or $2.05 per diluted share, for the first nine months of fiscal 2017 compared to $9.69 million, or $2.00 per share, for the first nine months of fiscal 2016. 

The company also announced a quarterly cash dividend to NVEC shareholders of $1.00 per share of common stock, payable February 28, 2017 to shareholders of record as of January 30, 2017.

 NVE Corporation is followed by one firm. Their analysts rate shares of NVEC as a “Strong Buy” with a price target of $66. 

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/18/2017
Ticker Symbol GRVY
Last Price a/o 4:00 PM EST  $                    70.69
Average Volume 13,800
Market Cap #343.2 million
Sales $26.1 million
Shares Outstanding 4.8 million
Share Float 4.74 million
Shortable Yes
Optionable No
Inside Ownership 0.10%
Short Float 0.92%
Short Interest Ratio 3.15
Quarterly Return 26.64%
YTD Return 0.10%
Year Return 41.42%

Jazz Pharmaceuticals plc. (Nasdaq: JAZZ) Drops in After-Hours on FDA Approval of Generic

Jazz Pharmaceuticals plc – Nasdaq: JAZZ

Ireland-based Jazz Pharmaceuticals dropped over 10% in after-hours trading on news that the FDA approved the first generic version of Jazz’s Xyrem oral solution to treat cataplexy and excessive daytime sleepiness in patients with narcolepsy. Jazz Pharmaceuticals trades on the Nasdaqunder ticker symbol JAZZ. Shares closed the regular session at $115.57 but reached $99.82 in after-hours trading.

Jazz Pharmaceuticals plc is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing, and commercializing meaningful products that address unmet medical needs. The company has a diverse portfolio of products and product candidates, with a focus in the areas of sleep and hematology/oncology. Jazz Pharmaceuticals also supports commercial products in other therapeutic areas.

Since 2011 Jazz Pharmaceuticals have reported increasing sales. In 2011 they reported $270 million and in 2015 JAZZ sales were $1.32 Billion. JAZZ EPS has been positive since 2011 and last year had their best performance with JAZZ earning $5.38 EPS. Twelve firms follow Jazz Pharmaceuticals. Eleven rate JAZZ a “Strong Buy” and one rates it as a “Hold”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/17/2017
Ticker Symbol JAZZ
Last Price a/o 5:04 PM EST  $                  111.50
Average Volume 638,750
Market Cap $6.94 Billion
Sales $1.43 Billion
Shares Outstanding 60 million
Share Float 58.5 million
Shortable Yes
Optionable Yes
Inside Ownership 2.60%
Short Float 2.21%
Short Interest Ratio 2.02
Quarterly Return -2.34%
YTD Return 6.00%
Year Return -7.10%

Pulmatrix, Inc. (Nasdaq: PULM) Rockets on FDA Designation

Pulmatrix, Inc. – Nasdaq: PULM

The U.S, Food and Drug Administration designated Pulmatrix’s PUR1900 a Qualified Infectious Disease Product (QIDP) for the treatment of respiratory infections in cystic fibrosis patients. The news sent Pumatrix shares, traded on the Nasdaq under ticker PULM, up over 100% in early trading. The FDA QIPD status confers an accelerated review and a five-year market exclusivity.

Pulmatrix Inc. develops inhaled therapies to address serious pulmonary disease using their clinically validated, proprietary iSPERSE technology. iSPERSE is a, dry powder technology developed, patented and validated by Pulmatrix scientists and engineers to improve how drugs are directed into the lungs. iSPERSE products are designed to maximize local drug concentrations and reduce systemic side effects, in order to make possible a new generation of inhaled therapies to improve patient outcomes.

Pulmatrix, Inc., nor PULM shares, are followed or rated by any firms or analysts. PULM EPS has been negative since 2011 with Pulmatrix reporting no sales.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

 

Forward Pharma (Nasdaq: FWP) Receives $1.25 Billion Lawsuit Settlement From Biogen

Forward Pharma – Nasdaq: FWP

Forward Pharma shares rocketed up over 60% from their Friday close of $18.35 on news of a patent-infringement lawsuit settlement with Biogen (BIIB). The Danish company trades on the Nasdaq as an American Depository Share (ADR). According to reports, Biogen will pay Forward Pharma $1.25 Billion to settle the ongoing lawsuit over their multiple sclerosis drug Tecfidera.

Forward Pharma is a Danish biotechnology company focused on the immunomodulatory compound dimethyl fumarate and derivatives, for applications as a pharmaceutical drug product to treat immune disorders such as multiple sclerosis and psoriasis. Major partners listed on Forward Pharma’s website include venture capital firms such as Nordic Biotech, Rosetta Capital, and BVF Partners.

Two firms follow Forward Biopharma and each rate FP shares as a “Strong Buy” despite no reported sales and negative EPS since 2012. Their consensus price target for FWP is $42.50.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/17/2017
Ticker Symbol FWP
Last Price a/o 11:29 AM EST $27.99
Average Volume 9,500
Market Cap $853 million
Sales
Shares Outstanding 46.5 million
Share Float 10.5 million
Shortable Yes
Optionable No
Inside Ownership
Short Float 0.83%
Short Interest Ratio 9.14
Quarterly Return -11.57%
YTD Return 22.33%
Year Return 18.46%

Top 10 Nasdaq Sm Cap Shorted Shares – Ending Jan 13, 2017

Week Ending 1/13/2017 – Most Shorted Nasdaq Small Caps

“Float” – Floating stock is calculated by subtracting closely-held shares and restricted stock from a firm’s total outstanding shares.

“Short Float” – the number of shorted shares divided by the number of floating shares.

“Short Ratio” – the number of shares that have been sold short and not yet covered – typically expressed as a percentage of the average daily trading volume.